The grades of 9 Biotechnology stocks are on the rise this week on Portfolio Grader. Each of these stocks is rated an “A” (“strong buy”) or “B” overall (“buy”).
This week, Anacor Pharmaceuticals, Inc. (ANAC) pushes up from a B to a A rating. Anacor Pharmaceuticals, Inc. focuses on discovering, developing, and commercializing small-molecule therapeutics derived from boron chemistry platform. The company also gets A’s in sales growth, earnings surprise, and earnings momentum. For more information, get Portfolio Grader’s complete analysis of ANAC stock.
Radius Health Inc (RDUS) earns a A this week, jumping up from last week’s grade of B. For more information, get Portfolio Grader’s complete analysis of RDUS stock.
Neurocrine Biosciences, Inc. (NBIX) improves from a B to a A rating this week. Neurocrine Biosciences, Inc. is focused on the discovery and development of therapeutics for neuropsychiatric, neuroinflammatory, and neurodegenerative diseases and disorders. The company also gets A’s in earnings surprise. For more information, get Portfolio Grader’s complete analysis of NBIX stock.
This week, Loxo Oncology Inc’s (LOXO) ratings are up from a B last week to a A. For more information, get Portfolio Grader’s complete analysis of LOXO stock.
The rating of Retrophin, Inc. (RTRX) moves up this week, rising from a B to a A. The company also gets A’s in sales growth and earnings revisions. For more information, get Portfolio Grader’s complete analysis of RTRX stock.
Halozyme Therapeutics, Inc. (HALO) boosts its rating from a B to a A this week. Halozyme Therapeutics, Inc. is a biopharmaceutical company developing products for the diabetes, cancer, dermatology and drug delivery markets. The company also gets A’s in sales growth and earnings revisions. For more information, get Portfolio Grader’s complete analysis of HALO stock.
Xencor, Inc. (XNCR) shows solid improvement this week. The company’s rating rises from a C to a B. The company also gets A’s in sales growth and earnings surprise. For more information, get Portfolio Grader’s complete analysis of XNCR stock.
Lexicon Pharmaceuticals, Inc. (LXRX) is seeing ratings go up from a B last week to a A this week. Lexicon Pharmaceuticals, Inc. researches treatments for diabetes and obesity, cardiovascular disease, psychiatric and neurological disorders, cancer, immune system disorders, and ophthalmic disease. The company also gets A’s in sales growth. For more information, get Portfolio Grader’s complete analysis of LXRX stock.
Recro Pharma, Inc.’s (REPH) ratings are looking better this week, moving up to a A from last week’s B. The company also gets A’s in earnings momentum. For more information, get Portfolio Grader’s complete analysis of REPH stock.
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.
